BrainStorm Q1 2022 net loss $5.4M, cash $18.4M; progresses NurOwn ALS program

BRAINSTORM CELL THERAPEUTICS INC.

2022-Q1 EPS reported -$0.15

Net loss $5.4M ($0.15/sh) improved from $6.7M ($0.19/sh) in Q1 2021.
Cash $18.4M at Mar 31, down from $22.1M at Dec 31, 2021.
R&D spend cut to $2.6M from $4.3M; G&A rose to $2.9M from $2.6M.
Presented Phase 3 NurOwn biomarker data at AAN 2022; genetic analysis at MDA conference.
Appointed Netta Blundheim-Shraga as VP R&D and Antal Pearl-Lendener as Chief Legal Counsel.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BRAINSTORM CELL THERAPEUTICS INC. reported first quarter ended March 31, 2022 results: net income approximately $5.4 million, EPS $0.15.

Period: first quarter ended March 31, 2022
Net income: approximately $5.4 million
EPS: $0.15
Result: reported results

Exact text from the filing

Net loss for the three months ended March 31, 2022, was approximately $5.4 million, as compared to a net loss of approximately $6.7 million for the three months ended March 31, 2021. Net loss per share for the three months ended March 31, 2022, and 2021 was $0.15 and $0.19 respectively.

View on SEC.gov

16 earnings releases filed in the last 30 days. Browse all earnings releases →

BRAINSTORM CELL THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001104659-22-060822

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.